Drug screening using model systems: some basics by Cagan, Ross
EDITORIAL
Drug screening using model systems: some basics
Ross Cagan*
ABSTRACT
An increasing number of laboratories that focus on model systems
are considering drug screening. Executing a drug screen is
complicated enough. But the path for moving initial hits towards
the clinic requires a different knowledge base and even a different
mindset. In this Editorial I discuss the importance of doing some
homework before you start screening. 'Lead hits', 'patentable
chemical space' and 'druggability' are all concepts worth exploring
when deciding which screening path to take. I discuss some of the
lessons I learned that may be useful as you navigate the screening
matrix.
The path to drug discovery
Recently, an increasing proportion of scientists, taxpayers and
funding agencies have emphasized the importance of moving basic
science towards the clinic. Simple model systems provide a
powerful tool for generating and exploring new concepts, and
new therapeutics. But the world of therapeutics is different from,
say, the world of fly genetics: the two worlds speak a different
language and, more importantly, they make different assumptions.
The path to drug development for academic scientists can be
daunting, even after identifying a therapeutic candidate that you
have decided is worth pursuing.
When my laboratory entered the world of drug discovery and
drug development, I knew basically nothing about ‘patentable
clinical space’, ADME studies (Box 1), or why screening
natural compounds might not always be a great idea. I assumed
that if we found drugs that ‘cured’ our fly disease models and
then accomplished the same in the mouse, the drug would
magically enter clinical trials. Somehow. Because it made
sense.
My goal in this piece is not to review how to screen drugs
using model systems – there are plenty of excellent reviews on
this subject already (Phillips and Westerfield, 2014; Gopinathan
et al., 2015; Asnani and Peterson, 2014; Veinotte et al., 2014;
Lasserre et al., 2015; Simon and Bedalov, 2004; Kaletta and
Hengartner, 2006; Yadav et al., 2016). My goal is to share some
of the knowledge my group has gained over the years on how to
think about drug screening. If you are asking the same question I
asked a decade ago – “Why didn’t anyone explain this to me
before we started?” – this Editorial is for you.
Getting started
The first question you need to ask yourself is: why do I want to do
drug screening? If the answer is “to build tools” for exploring basic
biology, then specificity trumps druggability. If it is “to satisfy
funding agencies”, well, good luck with that. Here, I focus on
researchers who have the goal of developing treatments for patients.
Let’s start with some basic terms:
Drug versus compound: pharma types are sticklers on this
point. Drugs are approved for patient use; in the United States that
means approved by the Food and Drug Administration (FDA). If
you are using a chemical library your hits are compounds; your next
step is to mature that initial compound into a lead compound or
lead hit.
Therapeutic index (TI): this is the ratio of efficacy (how
effective is the drug?) and toxicity (how toxic?) at optimal doses.
This often leads to a discussion of the therapeutic window of the
compound, i.e. the dose range at which a compound helps the
patient without significantly harming them.
Druggable space: does the structure of your compound look like
other drugs? Some structures are known to be toxic, and most
chemical structures are too large, too small, or just do not look like
they would have biological activity or that a chemist could easily
make more of it (see ‘natural compounds’ below). Instead, you want
to work in druggable space; that is, the compounds in your library
roughly look like drugs that work in people. Incidentally, you will
hear mention of Lipinski’s rule of five; I recommend you look this
one up (Box 2), then casually drop the phrase next time you talk to a
chemist.
Curing the disease without killing the patient
If you have identified a target and you want to identify a drug, the
first objective is to check whether a company is interested in
developing a lead. Drug companies are amazing at developing
targeted therapies: some will screen millions of compounds, and
they have teams of computational chemists to help. Another
important check: is your target likely to be the best therapeutic
candidate for the disease? The driver of a disease is not necessarily
the best therapeutic target, and the potential for toxicity is a key
consideration. Most drug delivery systems – commonly an injection
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or pill – drug the whole body. Will the patient be OK if your target is
partially suppressed throughout the body? Fully suppressed? By
some estimates, most drugs fail owing to toxicity, not poor efficacy.
Companies are increasingly pushing for knockdown of candidate
targets in adult mice so that any toxic effects at the organismal level
can be fully recognized.
In general, be prepared to honestly and frankly assess the
strengths and weaknesses of each of the platforms that you used to
validate your lead. For example, success in a mouse model is a good
start, but you should be prepared to discuss the statistics of how
predictive this is for clinical success. Many companies and investors
like to see leads that show good efficacy in a variety of models. Be
sure to benchmark your lead against the current standard-of-care
therapeutic.
Imagine the clinical trials
Planning the path to clinical trials is one of the hardest lessons to
grasp when embarking on a therapeutics screen; it certainly was for
me. If you have not fully explored the path by which your best lead
hits will enter clinical trials, please stop screening. Clinical trials are
expensive and time-consuming – they can require tens or even
hundreds of millions of dollars and many years to implement. Some
questions to consider:
Who will run the clinical trials? For major diseases,
pharmaceutical companies or large biotechnology companies will
most often finance and run later-stage trials. Getting their attention
can be difficult, although liaisons between pharma and research
institutes are becoming more common, especially for drug targets.
Remember, most drug companies do not have sufficient resources to
develop all of their own promising leads, for which they fully own
the intellectual property (IP). The IP of your lead compound is
typically owned by your institution, so you are already facing an
uphill battle to attract interest.
One great piece of advice that I was given is to engage
scientists at drug companies early on, even before you begin
screening. Their scientists are smart, savvy about drug screening
(especially the chemists) and often happy to give advice.
Developing a relationship can be helpful throughout the
screening process, and you are less of an unknown when you
later have leads to discuss.
Is there sufficient need for a new therapeutic? Most diseases
would benefit from improvements to available therapeutics, but
you should be aware that approved therapeutics raise the bar on
how great your therapeutic needs to be. Some diseases have several
approved therapies; even if these therapies are not perfect, their
existence will make investors less likely to invest in a new
candidate.
The special case of orphan diseases: a great role for basic
researchers is to develop drugs for orphan/rare diseases, defined in
the United States as affecting fewer than 200,000 people. Although
drug companies are taking on more orphan diseases, there are
thousands of diseases in which people need help but the disease is
too rare to attract attention. Fortunately, criteria for clinical trials are
designed to attract interest into this space, so the trials are quicker
and cheaper. Importantly, make sure that enough patients can be
located to run a trial. Many trials fail due to lack of patient
recruitment, and any investor considering your lead will want to
hear that you have thought about this.
Choosing a library
One of the most important and difficult decisions you will make is
choosing a library to screen. When my laboratory started down this
road, some kind scientists and chemists from pharma patiently
explained some basic principles, for which I am eternally grateful.
Please note there are varying opinions on the best libraries to use,
and the following points are meant to stimulate an awareness of
some the issues to consider.
FDA-approved drugs: one popular approach is to screen
libraries of FDA compounds. The Center for Personalized
Cancer Therapeutics at Mount Sinai uses a library of 1200
FDA-approved compounds to identify patient-specific cancer
therapies. There are many technical issues to consider, beyond
cost. For example, DMSO – the commonly used drug solvent – is
toxic to Drosophila at fairly low concentrations, so most libraries
are too dilute for our needs. Some tinkering before you purchase
is important.
The advantage of identifying an FDA-approved drug is speed to
patient. Issues relating to druggability, dosing and other parameters
have already been worked out. Furthermore, if you are associated
with a hospital, your colleagues may be able to establish a small
early-stage trial fairly quickly. In the case of very rare diseases, for
Box 1. ADME properties
Once you have identified a promising lead, you will need to begin thinking
about identifying its ADME (absorption, distribution metabolism and
excretion; see below) properties. There are several contract research
organizations (CROs) that will provide a preliminary assessment of the
ADME properties of your compound for a reasonable amount of money.
Larger scale ‘investigational new drug (IND)-enabling’ studies will be
considerably more expensive. Having ADME datawill change the level of
conversation you will have with potential partners and investors.
The acronym stands for:
Absorption: how readily the compound enters the bloodstream. Poor
absorption means poor ‘bioavailability’.
Distribution: how readily the drug makes it through the body and to the
target tissue. For example, if your compound strongly binds to blood
albumen it may not be available to enter cells.
Metabolism: how quickly your compound is cleared from the
bloodstream. Up to a point, longer is better, preferably hours. A
compound that is clear in minutes by P450 enzymes in the liver will
need to be altered.
Excretion: this parameter measures how completely and efficiently the
compound or its metabolites is cleared from the body.
Having a lead compound that passes all of these ADME properties is
unusual. This is where having backup analogs is useful, and another
reason to have chemists as friends.
Box 2. Lipinski’s rule of five
Christopher Lipinski, a Pfizer chemist, developed this rule in 1997 to
identify characteristics commonly found in successful drugs. The rule
states that a successful lead should have at least three of the following
four (this is rule of five, not five rules) properties:
• Five or fewer hydrogen bond donors
• Ten (2×5) or fewer hydrogen bond acceptors
• The compound should be small, typically less than 500 Da
• The compound should be mildly lipophilic (the ‘five’ comes from the
requirement that the octanol-water partition coefficient have a log
value less than 5.
Pharmaceutical companies are increasingly willing to consider
compounds that violate this rule, but this is information that you should
be ready to supply if conversations advance.
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which finding enough patients to achieve statistical significance is
not possible, FDA-approved drugs may provide the most efficient
path forward.
However, FDA library screens also highlight some of the
frustrations that basic researchers can have with the screening
landscape. Most FDA-approved drugs will be off-patent by the time
they would be approved in new trials, so the pharma industry is less
excited to run an expensive clinical trial only to be faced with
competition from generics. Remember that the goal of pharmaceutical
companies is not to put themselves out of business. My personal
experience is that they are usually generous in supplying drugs and
know-how. The responsibility is ours to provide them with a way
forward, by choosing our screening library wisely, and by being
prepared to discuss the chemistry of our leads in an informed and
sophisticated manner.
Which brings us to compound libraries: when selecting a
library, remember that free is not always best. For example, some
academic libraries emphasize ‘broad chemical space’, that is, lots
of chemical variety. Avoid these. You want a library of chemicals
that ‘sit in druggable space’ (for example, see Box 2 on Lipinski’s
rule of five). Importantly, you also want a chemical library in
which each compound is backed by additional related analogs
(usually available for a small fee), allowing you to ‘explore the
local chemical space’ surrounding your initial hit. This is key both
to generate better hits in your model system and also to give you
more compounds to work with, for example, as you explore human
cell lines. Also, investors like to know that you have backup
compounds should your lead have fundamental flaws such as poor
solubility.
Drug cocktails: cocktails provide a great opportunity for
‘polypharmacology’, i.e. to hit multiple therapeutic targets. My
laboratory is heavily invested in the idea that diseases are usually
complex, and can often benefit from targeting multiple parts of a
disease network through polypharmacology. However, if you are
looking to create drug cocktails, make sure you explore the IP
issues. Getting two companies to collaborate on a clinical trial is
becoming somewhat more common, but remains the exception.
There are other issues to consider, such as unexpected drug
interactions and the requirement for higher manufacturing
tolerances. If you are looking to pair your novel drug with an
approved drug, the same IP challenges emerge: will the company
support the trial? Better to find out early. Also, notice how IP issues
keep emerging. If you are screening for therapeutics and you want to
help patients, become an expert in IP.
A side note here about targets: efficacy is the most important
consideration, but knowing the direct targets and mechanism of
action of your lead will help gain the attention of chemists. My
experience is that many industry partners are only interested in
drugs that hit a small number of defined targets; they most
often prefer a ‘clean’ lead that hits a single target. I would like
that to change – many of the most successful drugs in the
clinics are not clean – but pharma continues to evolve slowly
on this point.
Natural compounds – a good idea? When I first explored
drug screening, many of my academic colleagues strongly
promoted screening natural compounds. My drug company
peers are not so enthusiastic. Most natural compounds are
complex molecules that are difficult to synthesize to patient
grade in a laboratory. As one colleague explained: “We spent
20 years learning how to synthesize taxol. We are not doing that
again”. While that is a bit extreme, remember that the more
difficult you make the chemistry, the lower the likelihood is that
your lead hits will move forward. Even in fields with large
markets, most clinical trials fail, so the months or years of effort
to synthesize a complex molecule can be difficult to justify.
Your first hit is a great start, but just a start
This section could just as easily be labeled ‘make friends with
chemists’. In fact, while I’m thinking about it, a shout out to my
chemist friends. (Always be nice to chemists!) In return, they will:
• tell you if your drug is in fact in druggable space
• move your drug into patentable chemical space
• make analogs to ‘play in the chemical space’
• properly speak to chemists when you engage pharma
• help you write a patent to protect your lead hit
• identify a corporate research organization for preliminary
ADME studies, the first step towards investigational new drug
(IND)-enabling studies.
• read your commentaries and make helpful suggestions (thanks
Arvin).
I have been fortunate to work with smart chemists who are also
interested in the biology, including Arvin Dar, Bob Devita,
Avner Schlessinger and Kevan Shokat. If you can find chemists
who will work with you to the level of understanding the
biology, then set up regular meetings and listen to what they have
to say.
IP and patentable chemical space
I will not tackle the intricacies of IP here, but let’s talk about some
basic points. You have screened and you have a hit. You don’t care
at all about making money; indeed, the idea makes you
uncomfortable and you worry that it will skew your science. You
should file that patent anyway.
If you have not – or cannot – patent your lead compound, then
patients will not benefit from your work. In fact, if you publish the
compound without patenting it you are actively preventing anyone
from benefiting therapeutically by blocking the ability of the
chemical space to be protected. No intellectual property, no clinical
trial. Unless you have the millions of dollars required to move the
drug forward by yourself, get it patented.
The take-home message
Drug discovery can be a rewarding outcome to a line of research.
My best advice is to be intentional about each step. Research the
whole road forward, and engage experts. Often, the rules of
engagement are not intuitive. Chemists and people in pharma can
speak a different language from your academic colleagues, in part
because they understand the long and complex road required for
success. But they are often willing to mentor because, like the rest of
us, they want to help patients. By doing a bit of homework before
you start screening, you can ensure that your ‘lead hit’ sits in
‘patentable chemical space’, creating a smoother path to clinical
trials.
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